Alexander Shulgin

Overview

Alexander Shulgin is presented in the source as the chemist who rediscovered and explored MDMA decades after its early synthesis and helped move knowledge of the compound into a small therapeutic and medical network.

Current Profile

In The Science of MDMA & Its Therapeutic Uses: Benefits & Risks, Shulgin functions as a bridge between laboratory chemistry, self-experimentation, underground therapeutic interest, and the later clinical-research history of MDMA. His book PIHKAL is named as a historical source on phenethylamine chemistry and experience. The episode does not supply a complete biography, publication history, or ethical assessment of his methods.

Key Characteristics

• Chemist associated with MDMA’s modern rediscovery and exploration.
• Shared compounds and observations within a circle that included therapists and physicians.
• Connected chemical experimentation to later therapeutic interest in MDMA.
• Co-authored PIHKAL, cited in the episode as a history and chemistry source.

Evidence

• Rediscovery role - The Science of MDMA & Its Therapeutic Uses: Benefits & Risks places Shulgin after Merck’s early synthesis and before modern clinical research.
• Therapeutic-network role - The Science of MDMA & Its Therapeutic Uses: Benefits & Risks says he shared compounds with a small group including therapists and physicians.
• Publication role - The Science of MDMA & Its Therapeutic Uses: Benefits & Risks identifies PIHKAL as a source on phenethylamine history, chemistry, and effects.

Qualifications

This profile is grounded in one condensed podcast source and should not be read as a full biography or endorsement of self-experimentation, informal distribution, or unsupervised psychoactive-drug use.

What Changed

• Created a bounded profile of Shulgin’s role in MDMA’s modern history.

Relationships

• MDMA - compound whose modern rediscovery and therapeutic circulation the source associates with Shulgin.
• Multidisciplinary Association for Psychedelic Studies - later institutional branch of the clinical-research history described in the episode.
• Psychedelic Clinical Supervision Boundary - safety and evidence boundary separating historical experimentation from clinical use.